A Phase 2 interventional study of Zanubrutinib and Rituximab in Marginal Zone Lymphoma, Follicular Lymphoma and Diffuse Large B-Cell Lymphoma, sponsored by BeiGene. Completed at 4 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-26.
Sponsored by BeiGene · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Lymphoma, B-Cell, Marginal Zone with a site in China — 35 open to participants now, 43 under way, 4 of them phase 3. Lymphoma, B-Cell, Marginal Zone · China.
Among the 58 studies in Lymphoma, B-Cell, Marginal Zone with a site in China, this one is the 42nd largest by enrollment of the 53 interventional ones that give a count, is one of 2 that started in 2018, is one of 31 in phase 2, and was the 2nd registered.
875 studies on the registry are indexed under Lymphoma, B-Cell, Marginal Zone; 111 are open to participants now.
Browse Lymphoma, B-Cell, Marginal Zone studies →35 of the 58 studies in Lymphoma, B-Cell, Marginal Zone with a site in China are open now. Recruiting first, the newest first:
Zhejiang Cancer Hospital · Sites in China
Ages 18+
Ascentage Pharma Group Inc. · Sites in China, United States
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
Beijing Tongren Hospital · Sites in China
Ages 18+
Henan Cancer Hospital · Sites in China
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 92 Lymphoma, B-Cell, Marginal Zone studies recruiting now, 77 (84%) set no upper age limit and 7 (8%) stop at 75 or younger; 9 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 36 · Phase 3 5 · Phase 4 2
First in 2014; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41 is close to the median of 40 across 681 interventional studies indexed under Lymphoma, B-Cell, Marginal Zone.
Median enrollment 68 across the 53 interventional studies, 500 across the 5 observational. Of the 12 that completed or were terminated, 5 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 58 have an industry lead sponsor. The 10 most frequent:
This study is registered under BeiGene, one of the names counted as BeOne Medicines. Under that name alone:
BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.
Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.
BeOne Medicines has 9 studies filed under Lymphoma, B-Cell, Marginal Zone — fewer than ten, so there is no comparison to draw.
11 of the studies in Lymphoma, B-Cell, Marginal Zone with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06647732Sun Yat-sen UniversityZanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT) | 2026-12-31 |
| NCT06134284Lixia ShengClinical Study of OR for Second-line Treatment of Refractory MZL | 2026-12-31 |
| NCT05006716BeOne MedicinesA Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies | 2027-03 |
| NCT07609446The First Affiliated Hospital of Soochow UniversityPomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma | 2027-04-30 |
| NCT06513234Institute of Hematology & Blood Diseases Hospital, ChinaCombination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas | 2027-06-21 |
Add all 11 to your calendar (.ics) → With an account.
Among the 58 studies in Lymphoma, B-Cell, Marginal Zone with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This was a multicenter, open-label, phase 2 study to evaluate efficacy, safety, and tolerability of BGB-3111 (zanubrutinib) 160 milligrams (mg) twice daily (BID) in combination with rituximab in Chinese participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) (non-GCB [non-germinal center B-cell-like] subtype) and R/R indolent lymphoma (follicular lymphoma [FL] and marginal zone lymphoma [MZL]).
Key Inclusion Criteria:
Participants meet the following criteria:
Laboratory parameters as specified below:
Key Exclusion Criteria:
Receipt of the following treatment prior to first dose of study drug:
Known infection with , or serologic status reflecting active or C infection as follows:
Note: Other protocol defined Inclusion/Exclusion criteria may have applied.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with non-GCB DLBCL received zanubrutinib plus rituximab for up to progressive disease or intolerance.
Drug: Zanubrutinib · Drug: Rituximab
Participants with R/R FL or MZL received zanubrutinib plus rituximab for up to progressive disease or intolerance.
Drug: Zanubrutinib · Drug: Rituximab
Administered zanubrutinib 160 mg orally (PO) BID continuously
Also known as: BGB-3111
Administered rituximab 375 mg/m\^2 intravenously on Cycle 1 Days 1, 8, 15, 22, and on Day 1 of Cycles 4, 6, 8, 10. Each cycle was 28 days long.
Overall Response Rate (ORR) As Measured By The Investigator
The percentage of participants whose best overall response met partial response (PR) or complete response (CR) criteria among all participants. The 95% confidence interval (CI) was calculated with the Clopper-Pearson method.
Time frame: Up to approximately 2.5 years
Duration Of Response (DOR) As Determined By Investigator
The DOR was defined as the time from the date that the response criteria were first met to the date that progressive disease (PD) was objectively documented or death, whichever occurred first. Medians were estimated by the Kaplan-Meier method with 95% CIs estimated using the Brookmeyer and Crowley method.
Time frame: Up to approximately 2.5 years
DOR: Event-free Rate
The DOR was defined as the time from the date that the response criteria were first met to the date that progressive disease (PD) was objectively documented or death, whichever occurred first. The event-free rate was estimated by the Kaplan-Meier method with 95% CIs estimated using Greenwood's formula.
Time frame: Up to approximately 2.5 years
Progression-free Survival (PFS) As Determined By Investigator
The PFS was defined as time from first dose of study treatment until first documentation of progression, assessed per the Lugano Classification, or death, whichever occurred first. Medians were estimated by the Kaplan-Meier method with 95% CIs estimated using the Brookmeyer and Crowley method.
Time frame: Up to approximately 2.5 years
PFS: Event-free Rate
The PFS was defined as time from first dose of study treatment until first documentation of progression, assessed per the Lugano Classification, or death, whichever occurred first. The event-free rate was estimated by the Kaplan-Meier method with 95% CIs estimated using Greenwood's formula.
Time frame: Up to approximately 2.5 years
Overall Survival (OS)
The OS was defined as the time from the date of first dose of study treatment to the date of death due to any cause. Medians were estimated by the Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.
Time frame: Up to approximately 2.5 years
OS: Survival Rate
The OS was defined as the time from the date of first dose of study treatment to the date of death due to any cause. Survival rates were estimated by the Kaplan-Meier method with 95% CIs estimated using Greenwood's formula.
Time frame: Up to approximately 2.5 years
Time To Response (TTR) As Determined By The Investigator
The TTR was defined as the time from the date of the first dose of study treatment to the date of the first qualifying response (partial response or better).
Time frame: Up to approximately 2.5 years
Median TTR
The TTR was defined as the time from the date of the first dose of study treatment to the date of the first qualifying response (partial response or better).
Time frame: Up to approximately 2.5 years
Complete Response Rate As Determined By The Investigator
The percentage of participants whose best overall response met complete response or complete metabolic response criteria among all participants are reported. The 95% CI was calculated with Clopper-Pearson method.
Time frame: Up to approximately 2.5 years
Number Of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) And Serious TEAEs
A treatment-emergent adverse event was defined as an adverse event with an onset or worsening (if present pretreatment) starting on or after the first dose of study drug up to 30 days after discontinuation of zanubrutinib or 90 days after discontinuation of rituximab, whichever occurred later; or initiation of new anticancer therapy if it occurred prior to the other 2 dates. Worsening of a treatment-emergent adverse event to Grade 5 beyond Day 30 after the last dose of zanubrutinib or Day 90 after the last dose rituximab was also considered a treatment-emergent adverse event if the event occurred prior to initiation of new anticancer therapy.
Time frame: Up to approximately 2.5 years
This study was conducted at 4 study centers in China, all of which enrolled participants. The first enrolled participants received their first dose on 04 January 2018, and the last participant enrolled received their first dose on 20 December 2018. A total of 41 participants with non-Hodgkin lymphoma (NHL) were enrolled into the study, and all received ≥1 dose of study treatment.
| Milestone | Relapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma | Relapsed/Refractory Follicular Lymphoma | Relapsed/Refractory Marginal Zone Lymphoma |
|---|---|---|---|
| Started | 20 | 16 | 5 |
| Received at least 1 dose of study drug | 20 | 16 | 5 |
| Completed | 0 | 0 | 0 |
| Not completed | 20 | 16 | 5 |
| Withdrew: Death | 13 | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 1 | 0 |
| Withdrew: Study terminated by the sponsor | 5 | 14 | 5 |
The percentage of participants whose best overall response met partial response (PR) or complete response (CR) criteria among all participants. The 95% confidence interval (CI) was calculated with the Clopper-Pearson method.
| Percentage of Participants | Relapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma | Relapsed/Refractory Follicular Lymphoma | Relapsed/Refractory Marginal Zone Lymphoma |
|---|---|---|---|
| Overall Response Rate (ORR) As Measured By The Investigator | 35 (15.4 to 59.2) | 56.3 (29.9 to 80.2) | 60.0 (14.7 to 94.7) |
The DOR was defined as the time from the date that the response criteria were first met to the date that progressive disease (PD) was objectively documented or death, whichever occurred first. Medians were estimated by the Kaplan-Meier method with 95% CIs estimated using the Brookmeyer and Crowley method.
| Months | Relapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma | Relapsed/Refractory Follicular Lymphoma | Relapsed/Refractory Marginal Zone Lymphoma |
|---|---|---|---|
| Duration Of Response (DOR) As Determined By Investigator | 8.79 (0.72 to NA) | NA (5.45 to NA) | 22.18 (8.31 to NA) |
The DOR was defined as the time from the date that the response criteria were first met to the date that progressive disease (PD) was objectively documented or death, whichever occurred first. The event-free rate was estimated by the Kaplan-Meier method with 95% CIs estimated using Greenwood's formula.
| Percentage of Participants | Relapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma | Relapsed/Refractory Follicular Lymphoma | Relapsed/Refractory Marginal Zone Lymphoma |
|---|---|---|---|
| 6 months | 50.0 (11.1 to 80.4) | 88.9 (43.3 to 98.4) | 100.0 (NA to NA) |
| 9 months | 50.0 (11.1 to 80.4) | 77.8 (36.5 to 93.9) | 66.7 (5.4 to 94.5) |
| 12 months | 50.0 (11.1 to 80.4) | 64.8 (25.3 to 87.2) | 66.7 (5.4 to 94.5) |
| 15 months | 33.3 (4.6 to 67.6) | 51.9 (16.4 to 78.8) | 66.7 (5.4 to 94.5) |
| 18 months | 33.3 (4.6 to 67.6) | 51.9 (16.4 to 78.8) | 66.7 (5.4 to 94.5) |
| 24 months | NA (NA to NA) | NA (NA to NA) | 33.3 (0.9 to 77.4) |
The PFS was defined as time from first dose of study treatment until first documentation of progression, assessed per the Lugano Classification, or death, whichever occurred first. Medians were estimated by the Kaplan-Meier method with 95% CIs estimated using the Brookmeyer and Crowley method.
| Months | Relapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma | Relapsed/Refractory Follicular Lymphoma | Relapsed/Refractory Marginal Zone Lymphoma |
|---|---|---|---|
| Progression-free Survival (PFS) As Determined By Investigator | 3.38 (2.69 to 5.49) | 11.10 (5.49 to NA) | 24.87 (11.01 to NA) |
The PFS was defined as time from first dose of study treatment until first documentation of progression, assessed per the Lugano Classification, or death, whichever occurred first. The event-free rate was estimated by the Kaplan-Meier method with 95% CIs estimated using Greenwood's formula.
| Percentage of Participants | Relapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma | Relapsed/Refractory Follicular Lymphoma | Relapsed/Refractory Marginal Zone Lymphoma |
|---|---|---|---|
| 6 months | 17.4 (4.3 to 37.7) | 73.3 (43.3 to 89.1) | 100.0 (NA to NA) |
| 9 months | 17.4 (4.3 to 37.7) | 66.7 (37.5 to 84.6) | 100.0 (NA to NA) |
| 12 months | 17.4 (4.3 to 37.7) | 46.7 (21.2 to 68.7) | 80.0 (20.4 to 96.9) |
| 15 months | 17.4 (4.3 to 37.7) | 46.7 (21.2 to 68.7) | 60.0 (12.6 to 88.2) |
| 18 months | 11.6 (2.0 to 30.7) | 40.0 (16.5 to 62.8) | 60.0 (12.6 to 88.2) |
| 24 months | 11.6 (2.0 to 30.7) | 40.0 (16.5 to 62.8) | 60.0 (12.6 to 88.2) |
The OS was defined as the time from the date of first dose of study treatment to the date of death due to any cause. Medians were estimated by the Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.
| Months | Relapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma | Relapsed/Refractory Follicular Lymphoma | Relapsed/Refractory Marginal Zone Lymphoma |
|---|---|---|---|
| Overall Survival (OS) | 11.20 (5.39 to 24.44) | NA (NA to NA) | NA (NA to NA) |
The OS was defined as the time from the date of first dose of study treatment to the date of death due to any cause. Survival rates were estimated by the Kaplan-Meier method with 95% CIs estimated using Greenwood's formula.
| Percentage of Participants | Relapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma | Relapsed/Refractory Follicular Lymphoma | Relapsed/Refractory Marginal Zone Lymphoma |
|---|---|---|---|
| 6 months | 72.7 (46.3 to 87.6) | 93.3 (61.3 to 99.0) | 100.0 (NA to NA) |
| 9 months | 55.9 (30.8 to 75.0) | 93.3 (61.3 to 99.0) | 100.0 (NA to NA) |
| 12 months | 44.7 (21.8 to 65.4) | 93.3 (61.3 to 99.0) | 100.0 (NA to NA) |
| 15 months | 33.6 (13.8 to 54.8) | 93.3 (61.3 to 99.0) | 100.0 (NA to NA) |
| 18 months | 33.6 (13.8 to 54.8) | 93.3 (61.3 to 99.0) | 100.0 (NA to NA) |
| 24 months | 33.6 (13.8 to 54.8) | 93.3 (61.3 to 99.0) | 100.0 (NA to NA) |
The TTR was defined as the time from the date of the first dose of study treatment to the date of the first qualifying response (partial response or better).
| Months | Relapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma | Relapsed/Refractory Follicular Lymphoma | Relapsed/Refractory Marginal Zone Lymphoma |
|---|---|---|---|
| Time To Response (TTR) As Determined By The Investigator | 3.56 ± 2.054 | 6.15 ± 3.867 | 3.67 ± 1.631 |
The TTR was defined as the time from the date of the first dose of study treatment to the date of the first qualifying response (partial response or better).
| Months | Relapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma | Relapsed/Refractory Follicular Lymphoma | Relapsed/Refractory Marginal Zone Lymphoma |
|---|---|---|---|
| Median TTR | 2.79 (2.7 to 8.2) | 5.49 (2.6 to 13.8) | 2.73 (2.7 to 5.6) |
The percentage of participants whose best overall response met complete response or complete metabolic response criteria among all participants are reported. The 95% CI was calculated with Clopper-Pearson method.
| Percentage of Participants | Relapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma | Relapsed/Refractory Follicular Lymphoma | Relapsed/Refractory Marginal Zone Lymphoma |
|---|---|---|---|
| Complete Response Rate As Determined By The Investigator | 10.0 (1.2 to 31.7) | 18.8 (4.0 to 45.6) | 0.0 (0.0 to 52.2) |
A treatment-emergent adverse event was defined as an adverse event with an onset or worsening (if present pretreatment) starting on or after the first dose of study drug up to 30 days after discontinuation of zanubrutinib or 90 days after discontinuation of rituximab, whichever occurred later; or initiation of new anticancer therapy if it occurred prior to the other 2 dates. Worsening of a treatment-emergent adverse event to Grade 5 beyond Day 30 after the last dose of zanubrutinib or Day 90 after the last dose rituximab was also considered a treatment-emergent adverse event if the event occurred prior to initiation of new anticancer therapy.
| Participants | Relapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma | Relapsed/Refractory Follicular Lymphoma | Relapsed/Refractory Marginal Zone Lymphoma |
|---|---|---|---|
| Participants With at Least 1 TEAE | 20 | 16 | 5 |
| Serious TEAEs | 7 | 4 | 0 |
Collected over Day 1 through approximately 2.5 years. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Relapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma | 13/20 (65%) | 7/20 (35%) | 19/20 (95%) |
| Relapsed/Refractory Follicular Lymphoma | 1/16 (6.3%) | 4/16 (25%) | 16/16 (100%) |
| Relapsed/Refractory Marginal Zone Lymphoma | 0/5 (0%) | 0/5 (0%) | 5/5 (100%) |
| Event | Relapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma | Relapsed/Refractory Follicular Lymphoma | Relapsed/Refractory Marginal Zone Lymphoma |
|---|---|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/20 | 0/16 | 0/5 |
| Abdominal painGastrointestinal disorders | 2/20 | 0/16 | 0/5 |
| LymphangitisInfections and infestations | 0/20 | 1/16 | 0/5 |
| PneumoniaInfections and infestations | 0/20 | 1/16 | 0/5 |
| Pulmonary mycosisInfections and infestations | 0/20 | 1/16 | 0/5 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 1/20 | 1/16 | 0/5 |
| PyrexiaGeneral disorders | 0/20 | 1/16 | 0/5 |
| LymphadenopathyBlood and lymphatic system disorders | 0/20 | 1/16 | 0/5 |
| Hepatic function abnormalHepatobiliary disorders | 0/20 | 1/16 | 0/5 |
| HypoproteinaemiaMetabolism and nutrition disorders | 0/20 | 1/16 | 0/5 |
| Event | Relapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma | Relapsed/Refractory Follicular Lymphoma | Relapsed/Refractory Marginal Zone Lymphoma |
|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 1/20 | 3/16 | 4/5 |
| White blood cell count decreasedInvestigations | 5/20 | 5/16 | 3/5 |
| Neutrophil count decreasedInvestigations | 4/20 | 4/16 | 3/5 |
| Urinary tract infectionInfections and infestations | 0/20 | 2/16 | 2/5 |
| AnaemiaBlood and lymphatic system disorders | 4/20 | 3/16 | 2/5 |
| PyrexiaGeneral disorders | 1/20 | 3/16 | 2/5 |
| AstheniaGeneral disorders | 0/20 | 1/16 | 2/5 |
| HaematuriaRenal and urinary disorders | 0/20 | 4/16 | 2/5 |
| Abdominal pain upperGastrointestinal disorders | 5/20 | 1/16 | 1/5 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/20 | 4/16 | 0/5 |
| Age, Continuous(years) | Relapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma | Relapsed/Refractory Follicular Lymphoma | Relapsed/Refractory Marginal Zone Lymphoma | Total |
|---|---|---|---|---|
| Mean | 55.2 ± 15.00 | 47.6 ± 12.36 | 61.2 ± 8.87 | 53.0 ± 13.94 |
| Age, Customized(Participants) | Relapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma | Relapsed/Refractory Follicular Lymphoma | Relapsed/Refractory Marginal Zone Lymphoma | Total |
|---|---|---|---|---|
| <65 years | 14 | 15 | 3 | 32 |
| ≥65 years | 6 | 1 | 2 | 9 |
| Sex: Female, Male(Participants) | Relapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma | Relapsed/Refractory Follicular Lymphoma | Relapsed/Refractory Marginal Zone Lymphoma | Total |
|---|---|---|---|---|
| Female | 7 | 8 | 3 | 18 |
| Male | 13 | 8 | 2 | 23 |
| Race (NIH/OMB)(Participants) | Relapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma | Relapsed/Refractory Follicular Lymphoma | Relapsed/Refractory Marginal Zone Lymphoma | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 20 | 16 | 5 | 41 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Body Mass Index(kilogram/m^2) | Relapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma | Relapsed/Refractory Follicular Lymphoma | Relapsed/Refractory Marginal Zone Lymphoma | Total |
|---|---|---|---|---|
| Mean | 23.43 ± 2.652 | 25.04 ± 5.079 | 24.33 ± 4.813 | 24.17 ± 3.989 |
| Body Surface Area(m^2) | Relapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma | Relapsed/Refractory Follicular Lymphoma | Relapsed/Refractory Marginal Zone Lymphoma | Total |
|---|---|---|---|---|
| Mean | 1.72 ± 0.113 | 1.77 ± 0.295 | 1.69 ± 0.240 | 1.74 ± 0.213 |
| Eastern Cooperative Oncology Group Performance (ECOG)Status(Participants) | Relapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma | Relapsed/Refractory Follicular Lymphoma | Relapsed/Refractory Marginal Zone Lymphoma | Total |
|---|---|---|---|---|
| Grade 0 | 13 | 11 | 3 | 27 |
| Grade 1 | 5 | 4 | 2 | 11 |
| Grade 2 | 2 | 1 | 0 | 3 |
| Hepatitis B Core Antibody(Participants) | Relapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma | Relapsed/Refractory Follicular Lymphoma | Relapsed/Refractory Marginal Zone Lymphoma | Total |
|---|---|---|---|---|
| Positive | 6 | 3 | 2 | 11 |
| Negative | 14 | 13 | 2 | 29 |
| Missing | 0 | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Ran from Jan 2018 to primary completion in Aug 2020, 31 months.
Results were first posted in Oct 2021, 1 year 2 months after primary completion.
Of 113 phase 2 interventional studies under Lymphoma, B-Cell, Marginal Zone, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 110. This study's 31 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zanubrutinib
Lymphoma, B-Cell, Marginal Zone →